Vista, California -- AutoGenomics, Inc., announced today that it has named Salvatore V. Alberti as Chief Financial Officer.
Mr. Alberti has over 20 years of financial leadership experience in both privately-held and publicly owned companies. He has held roles as Chief Financial Officer, Corporate Controller, Senior Director of SEC Reporting, and International Controller and has held senior financial management positions with BeyondTrust Software, Solera Holdings, ActivIdentity and Linear Technology Corporation. Mr. Alberti has six years combined experience in public accounting with Ernst & Young and Deloitte. He holds a B.S. in Business Administration (Accounting) and a M.S. in Accountancy from San Diego State University. Mr. Alberti is a Certified Public Accountant in the State of California.
"We are very happy to welcome Sal to AutoGenomics" said Fareed Kureshy, AutoGenomics' President and Chief Executive Officer. "As we grow our business with the introduction of the INFINITI® High Throughput System (HTS) and expand our menu of tests, Sal's broad business background will be important as we seek to expand our investor base to capitalize on our leadership position in the molecular diagnostics market."
AutoGenomics Inc., a privately held company based in Vista, CA, designs, develops, manufactures and markets an automated, microarray-based multiplexing diagnostic platform that can be used to assess disease signatures with novel genomic and proteomic markers in the areas of personalized medicine, women's health, oncology, genetic disorders and infectious disease. With the discovery of genes and their link to various disease states, the AutoGenomics platform revolutionizes the way patients are diagnosed, monitored and managed, leading to a new and emerging era of personalized medicine and significant advances in drug selection and dosing.